ReviewSeminars in immunology2012
Chronic alloantibody mediated rejection.
Review in Seminars in immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 49 citations in OpenAlex.
- Heme oxygenase-1 modulates CD62E-dependent endothelial cell-monocyte interactions and mitigates HLA-I-induced transplant vasculopathy in mice.Frontiers in immunology · 2025Article
- Belatacept inhibit human B cell germinal center development in immunodeficient mice.Scientific reports · 2023Article
- Balancing B cell responses to the allograft: implications for vaccination.Frontiers in immunology · 2022Review
- Large Animal Models of Vascularized Composite Allotransplantation: A Review of Immune Strategies to Improve Allograft Outcomes.Frontiers in immunology · 2021Review
- Vascular Signaling in Allogenic Solid Organ Transplantation - The Role of Endothelial Cells.Frontiers in physiology · 2020Review
- Effector and regulatory B cells in immune-mediated kidney disease.Nature reviews. Nephrology · 2019Review
- Human Cytomegalovirus Infection Increases Both Antibody- and Non-Antibody-Dependent Cellular Reactivity by Natural Killer Cells.Transplantation direct · 2017Article
- T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway.Cellular & molecular immunology · 2017Article
- Desensitization: Overcoming the Immunologic Barriers to Transplantation.Journal of immunology research · 2017Review
- Transplantology: Challenges for Today.Archivum immunologiae et therapiae experimentalis · 2016Review
- Potential Roles for C1 Inhibitor in Transplantation.Transplantation · 2016Review
- B Cells, Antibodies, and More.Clinical journal of the American Society of Nephrology : CJASN · 2016Review
- Lupus-Prone Mice Resist Immune Regulation and Transplant Tolerance Induction.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2016Article
- ABO-compatible liver allograft antibody-mediated rejection: an update.Current opinion in organ transplantation · 2015Review
- Graft microvascular disease in solid organ transplantation.Journal of molecular medicine (Berlin, Germany) · 2014Review
- Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy.World journal of transplantation · 2014Article
- Lessons and limits of mouse models.Cold Spring Harbor perspectives in medicine · 2013Review
- Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2013Article
- The impact of donor-specific anti-HLA antibodies on late kidney allograft failure.Nature reviews. Nephrology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Alloantibodies clearly cause acute antibody mediated rejection, and all available evidence supports their pathogenic etiology in the development of chronic alloantibody mediated rejection (CAMR). But the slow evolution of this disease, the on-going immunosuppression, the variations in titer of alloantibodies, and variation in antigenic targets all complicate identifying which dynamic factors are most important clinically and pathologically. This review highlights the pathological factors related to the diagnosis of CAMR, the time course and natural history of this disease. What is known about CAMR pathogenesis is discussed including alloantibodies, the role of complement, gene activation, and Fc effector cell function. Therapy, which is problematic for this disease, is also discussed, including on-going and potential therapies and their limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.